Off-label use of medicine in pediatrics: Focus on gastrointestinal diseases

Current Opinion in Pediatrics

Volumn 25, Issue 5, 2013, Pages 612-617

  Karesh, Alyson ^a   Tomaino, Juli ^b   Mulberg, Andrew E ^b  

^a Pediatric and Maternal Health Staff   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Drug development; Gastrointestinal; Off label; Pediatric

Indexed keywords

ADALIMUMAB; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CERTOLIZUMAB PEGOL; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LANSOPRAZOLE; MACROGOL 3350; METOCLOPRAMIDE; PROTON PUMP INHIBITOR; GASTROINTESTINAL AGENT;

ACUTE GASTROENTERITIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILDHOOD DISEASE; CONSTIPATION; CROHN DISEASE; DRUG INDUSTRY; DRUG PACKAGING; ENTERITIS; EOSINOPHILIC ESOPHAGITIS; FOOD AND DRUG ADMINISTRATION; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HUMAN; LAW; OFF LABEL DRUG USE; PEDIATRICS; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REFLUX ESOPHAGITIS; REVIEW; ULCERATIVE COLITIS; UNITED STATES; CHILD; CLINICAL PRACTICE; GASTROINTESTINAL DISEASES; LEGISLATION AND JURISPRUDENCE; PRESCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; OFF-LABEL USE; PEDIATRICS; PRACTICE PATTERNS, PHYSICIANS'; UNITED STATES;

EID: 84888298410     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328363ed4e     Document Type: Review

References (53)

1. Ruiz-Antoran B, Pineiro R, Avendano C, et al. Drug utilization and off-label drug use in Spanish pediatric gastroenterology outpatients. J Pediatr Gastroenterol Nutr 2013; 56:173-177.
2. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2012; 68:21-28.
3. Vanchieri C, Stith Butler A, Knutsen A. Address the barriers to pediatric drug development, workshop summary. Washington, DC: The National Academies Press; 2008; p. 8.
4. Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012; 87:982-990.
5. Sachs AN, Avant D, Lee CS, et al. Pediatric information in drug product labeling. JAMA 2012; 307:1914-1915.
6. Tobin Jr. Pediatric drug labeling: still an unfinished need. Anesth Analg 2012; 115:987-988.
7. Lenk C. Off-label drug use in paediatrics: a world-wide problem. Current Drug Targets 2012; 13:878-884.
8. Rocchi F, Paolucci P, Ceci A, Rossi P. The European paediatric legislation: benefits and perspectives. Italian J Pediatr 2010; 36:56.
9. Rocchi F, Tomasi P. The development of medicines for children. Part of a series on pediatric pharmacology. Guest edited by Zuccotti G, Clementi E, Molteni C. Pharmacol Res 2011; 64:169-175.
10. Wertheimer A. Off-label prescribing of drugs for children. Current Drug Safety 2011; 6:46-48.
11. Yamashiro Y, Martin J, Gazarian M, et al. Drug development: the use of unlicensed/off-label medicines in pediatrics. J Pediatr Gastroenterol Nutr 2012; 55:506-510.
12. Kemper EM, Merkus M, Wierenga PC, et al. Towards evidence-based pharmacotherapy in children. Pediatric Anesthesia 2011; 21:183-189.
13. Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr 2005; 164:552-558.
14. van den Berg H, Tak N. Licensing and labeling of drugs in a paediatric oncology ward. Brit J Clin Pharmacol 2011; 72:474-481.
15. Yang CP, Veltri MA, Anton B, et al. Food and Drug Administration approval for medications used in the pediatric intensive care unit: a continuing conundrum. Pediatr Crit Care Med 2011; 12:e195-e199.
16. McLay J, Tanaka M, Ekins-Daukes S, et al. A prospective questionnaire assessment of attitudes and experiences of off-label prescribing among hospital based paediatricians. Arch Dis Child 2006; 91:584-587.
17. Dell'Aera M, Gasbarro A, Padovano M, et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. PharmWorld Sci 2007; 29:361-367.
18. Zucker H, Rago L. Access to essential medicines for children: the World Health Organization's global response. Clin Pharmacol Ther 2007; 82:503-505.
19. Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007; 161:282-290.
20. Dick A, Keady S, Mohamed F, et al. Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment Pharmacol Ther 2003; 17:571-575.
21. Malcolm W, Cotten C. Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonates. Clin Perinatol 2012; 39:99-109.
22. Committee on pediatric studies conducted under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), Institute of Medicine of the National Academies. Safe and effective medicines for children, Pediatric studies conducted under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Field MJ, Boat TF, editors. Washington, DC: The National Academies Press; 2012. pp. 7, 61-62, 139-140.
23. Karesh A, Mulberg AE. US perspective on off-label use in pediatrics. J Pediatr Gastroenterol Nutr 2013; 56:113-114.
24. Stafford RS. Off-label use of drugs and medical devices: a review of policy implications. Clin Pharmacol Ther 2012; 91:920-925.
25. Kimland E, Odlind V. Off-label drug use in pediatric patients. Clin Pharmacol Ther 2012; 91:796-801.
26. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. Expert Opin Drug Saf 2012; 11:95-105.
27. Best Pharmaceuticals for Children Act of 2007 (BPCA), and Pediatric Research Equity Act of 2007 (PREA). 2013; http://www/fda/gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ucm049867.htm. [Accessed on 7 April 2013]
28. Snyder KM, Reaman G, Avant D, Pazdur R. The impact of the written request process on drug development in childhood cancer. Pediatr Blood Cancer 2013; 60:531-537.
29. FDA Safety and Innovation Act (FDASIA), Title V-Pediatric Drugs and Devices. 2013; http://www/fda/gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/ucm049867.htm. [Accessed on 7 April 2013]
30. Vernon JA, Shortenhaus SH, Mayer MH, et al. Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation. Pediatr Drugs 2012; 14:283-294.
31. Committee on pediatric studies conducted under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA), Institute of Medicine of the National Academies. Safe and effective medicines for children, Pediatric studies conducted under the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Field MJ, Boat TF, editors. Washington, DC: The National Academies Press; 2012. p. 2.
32. FDA New Pediatric Labeling Information Database. 2013; http://www. accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=labelingdatabase. [Accessed on 29 April 2013]
33. Rose K, Della Pasqua O. Development of paediatric medicines: concepts and principles. Handb Exp Pharmacol 2011; 205:111-124.
34. Boots I, Sukhai RN, Klein RH, et al. Stimulation programs for pediatric drug research: do children really benefit? Eur J Pediatr 2007; 166:849-855.
35. Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther 2008; 30:2133-2145.
36. Institute for Pediatric Innovation. 2013; http://pediatricinnovation.org. [Accessed on 29 April 2013]
37. Eunice Kennedy Shriver National Institute of Child Health and Human Development, Best Pharmaceuticals for Children Act. 2013; www.bpca.nichd.nih. gov. [Accessed on 29 April 2013]
38. Bazzano A, Mangione-Smith R, Schonlau M, et al. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009; 9:81-88.
39. Nexium (esomeprazole magnesium) Delayed-Release Capsules, Nexium (esomeprazole magnesium) Delayed-Release Suspension labeling. 2013; http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021153s044, 021957s014,022101s011lbl.pdf. Labeling approved 28 November 2012. [Accessed on 29 April 2013]
40. Chai G, Governdale L, McMahon A, et al. Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 2012; 130:23-31.
41. Chen I, Gao W, Johnson A, et al. Proton pump inhibitor use in infants: FDA reviewer experience. J Pediatr Gastroenterol Nutr 2012; 54:8-14.
42. Shakhnovich V, Ward R, Kearns G. Failure of proton pump inhibitors to treat GERD in neonates and infants: A question of drug, diagnosis, or design. Clin Pharmacol Ther 2012; 92:388-392.
43. Prevacid (lansoprazole) Delayed-Release Capsules, Prevacid SoluTab (lansoprazole) Delayed-Release Disintegrating Tablets labeling. 2013; Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 020406s078-021428s025lbl.pdf. Labeling approved 28 September 2012. [Accessed on 29 April 2013]
44. Reglan (metoclopramide) labeling. 2013; Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/017854s058lbl.pdf. Labeling approved 22 September 2011. [Accessed on 29 April 2013]
45. Zanon D, Gallelli L, Rovere F, et al. Off-Label prescribing patterns of antiemetics in children: A multicenter study in Italy. Eur J Pediatr 2013; 172:361-367.
46. Hoekman D, Benninga M. Functional constipation in childhood: current pharmacotherapy and future perspectives. Expert Opin Pharmacother 2013; 14:41-51.
47. Adamiak T, Altaf M, Jensen MK, et al. One-day bowel preparation with polyethylene glycol 3350: An effective regimen for colonoscopy in children. Gastrointest Endosc 2010; 71:573-577.
48. Terry N, Chen-Lim ML, Ely E, et al. Polyethylene glycol powder solution versus senna for bowel preparation for colonoscopy in children. J Pediatr Gastroenterol Nutr 2013; 56:215-219.
49. St. Louis C. Drugs for adults is popular as children's remedy. The New York Times 2012; A1, A14. http://www.nytimes.com/2012/05/26/us/miralax-apopular- cure-but-never-approved-for-children.- html?pagewanted=all&-r=0. [Accessed 26 May 2012]
50. Qizilbash N, Mendez I. Trends in utilization and off label use of polyethylene glycol 4000 laxatives and the prevalence of constipation in children in France. Clin Exp Gastroenterol 2011; 4:181-188.
51. Trinkley K, Porter K, Nahata M. Prescribing patterns for the outpatient treatment of constipation in the United States. Dig Dis Sci 2010; 55: 3514-3520.
52. DeBie C, Escher J, de Riddler L, et al. The duration of effect of infliximab maintenance treatment in pediatric Crohn's disease is limited. Aliment Pharmacol Ther 2011; 33:243-250.
53. Yang L, Alex G, Catto-Smit A. The use of biologic agents in pediatric inflammatory bowel disease. Curr Opin Pediatr 2012; 4:609-614.